Gilead Sciences has reported positive topline data from its Japanese Phase III trial of sofosbuvir (Sovaldi) in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
written on 03.04.2014
Gilead Sciences has reported positive topline data from its Japanese Phase III trial of sofosbuvir (Sovaldi) in combination with ribavirin for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.
See our Cookie Privacy Policy Here